<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7423094</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1008735</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-20-01063</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pearls</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Covid 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Antibody Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>SARS</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Clinical Laboratory Sciences</subject><subj-group><subject>Transfusion Medicine</subject><subj-group><subject>Blood Transfusion</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Transfusion Medicine</subject><subj-group><subject>Blood Transfusion</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacologic Analysis</subject><subj-group><subject>Pharmacokinetic Analysis</subject><subj-group><subject>Elimination Half-Life Calculation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Convalescent serum therapy for COVID-19:&#x000a0;A 19th century remedy for a 21st century disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6079-4277</contrib-id><name><surname>Montelongo-Jauregui</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5600-4367</contrib-id><name><surname>Vila</surname><given-names>Taissa</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5286-4562</contrib-id><name><surname>Sultan</surname><given-names>Ahmed S.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jabra-Rizk</surname><given-names>Mary Ann</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Maryland, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Dutch</surname><given-names>Rebecca Ellis</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Kentucky, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>dmontelongo@umaryland.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><volume>16</volume><issue>8</issue><elocation-id>e1008735</elocation-id><permissions><copyright-statement>&#x000a9; 2020 Montelongo-Jauregui et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Montelongo-Jauregui et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ppat.1008735.pdf"/><funding-group><funding-statement>The work in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number R01AI130170 (NIAID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="7"/></counts><custom-meta-group><custom-meta id="outbreaks"><meta-name>Outbreaks</meta-name><meta-value>COVID-19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec001"><title>Bridging the gap between now and then</title><p>Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that mysteriously emerged in late December 2019 in Wuhan City, China [<xref rid="ppat.1008735.ref001" ref-type="bibr">1</xref>, <xref rid="ppat.1008735.ref002" ref-type="bibr">2</xref>]. The virus quickly spread worldwide and was announced a global pandemic by the World Health Organization (WHO) in March 2020. Shortly after, a novel coronavirus was identified as the etiologic agent and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus to infect humans and the third to cause an outbreak [<xref rid="ppat.1008735.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="ppat.1008735.ref004" ref-type="bibr">4</xref>]. SARS-CoV-2 continues to spread around the world, as of late July, 2020, over 17 million people have been infected, causing over 665,000 deaths (<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/">https://coronavirus.jhu.edu/</ext-link>) and these numbers continue to trend upwards. Despite concerted global efforts, only a few targeted therapeutics, such as remdesivir, are available to help prevent or treat this disease [<xref rid="ppat.1008735.ref005" ref-type="bibr">5</xref>], therefore, convalescent plasma therapy, a century-old medical remedy is being revisited as a viable and immediate option for mitigating the impact of this disease [<xref rid="ppat.1008735.ref006" ref-type="bibr">6</xref>]. Convalescent plasma therapy is a type of passive antibody therapy whereby blood plasma with neutralizing antibodies against a specific virus is recovered from people who have recuperated from an infection, and administered to patients with the infection in order to improve clinical outcome [<xref rid="ppat.1008735.ref006" ref-type="bibr">6</xref>]. Although the potential clinical benefit of convalescent plasma therapy in COVID-19 is still uncertain, administering antibody-containing plasma from recovered patients is a near-term option that can be implemented relatively quickly. In fact, because of the high number of patients with severe COVID-19 and the mainstay of current clinical treatment consisting of symptomatic management and mechanical ventilation, administering convalescent plasma for treatment purposes is currently being deployed [<xref rid="ppat.1008735.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>]. Although it is still early to tell whether this therapeutic approach is effective against this disease, evidence so far has shown promise in critically ill patients [<xref rid="ppat.1008735.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="ppat.1008735.ref010" ref-type="bibr">10</xref>]. As new targeted therapies against COVID-19 take considerable time to develop, test and deploy, convalescent plasma therapy could buy time needed to develop more sophisticated targeted treatments.</p></sec><sec id="sec002"><title>Historical precedent for the use of antibody therapy</title><p>Prior to the antibiotic era, serum (plasma minus clotting factors) therapy was widely used to treat a range of infectious diseases such as scarlet fever and pneumococcal pneumonia. In 1890, the physiologists von Behring and Kitasato used blood serum from immunized animals to treat diphtheria and tetanus [<xref rid="ppat.1008735.ref013" ref-type="bibr">13</xref>]; subsequently, serum from recovered animals was identified as a possible source of specific antibodies [<xref rid="ppat.1008735.ref014" ref-type="bibr">14</xref>, <xref rid="ppat.1008735.ref015" ref-type="bibr">15</xref>]. The use of convalescent serum gained global recognition and revolutionized the way infectious diseases were treated, and in 1901, Emil von Behring was awarded the Nobel Prize for Medicine for his work, which served as a basis for treatment of multiple diseases in the 1900s as well as the development of vaccines [<xref rid="ppat.1008735.ref015" ref-type="bibr">15</xref>]. In fact, there are numerous examples throughout history in which convalescent serum was used with some degree of success to treat an array of diseases, including rheumatic fever [<xref rid="ppat.1008735.ref016" ref-type="bibr">16</xref>], scarlet fever [<xref rid="ppat.1008735.ref017" ref-type="bibr">17</xref>], mumps [<xref rid="ppat.1008735.ref018" ref-type="bibr">18</xref>], measles [<xref rid="ppat.1008735.ref018" ref-type="bibr">18</xref>, <xref rid="ppat.1008735.ref019" ref-type="bibr">19</xref>], chickenpox [<xref rid="ppat.1008735.ref018" ref-type="bibr">18</xref>], and pneumococcal and meningococcal infections [<xref rid="ppat.1008735.ref020" ref-type="bibr">20</xref>] (<xref ref-type="fig" rid="ppat.1008735.g001">Fig 1</xref>). Most notable use was during the Spanish Flu pandemic (1918 to 1920), where meta-analysis studies showed a significantly reduced mortality risk in patients treated with convalescent serum [<xref rid="ppat.1008735.ref008" ref-type="bibr">8</xref>, <xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>]. However, with the advent of antimicrobials, by the middle of the 20th century, the use of serum therapy had declined. Nevertheless, the interest in passive antibody therapy has been renewed periodically when new epidemics or pandemics have emerged. One example is during the Ebola virus (EBOV) outbreak in 1976 in the Democratic Republic of Congo, where an infected laboratory worker recovered after transfusion with convalescent plasma containing anti-EBOV antibodies. Similarly, in 1979, patients with Argentine hemorrhagic fever virus treated with convalescent plasma had a lower mortality rate compared with subjects treated with normal plasma, and similar results were reported for subsequent epidemics of the disease [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>]. Over the following decades, convalescent plasma therapy was successfully employed during the H1N1 swine influenza pandemic (2009), the H5N1 avian flu epidemic (2003), as well as during the EBOV outbreak in West Africa in 2013. Most relevant and encouraging is the use of convalescent plasma during 2 previous coronavirus epidemics: severe acute respiratory syndrome (SARS) in 2003, and Middle East respiratory syndrome (MERS) in 2012 [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>]. The high degree of success in achieving favorable clinical outcomes during these coronaviruses outbreaks establishes a strong precedent and supports the notion that convalescent plasma could be a viable option for treatment of COVID-19 patients, particularly upon early administration [<xref rid="ppat.1008735.ref006" ref-type="bibr">6</xref>, <xref rid="ppat.1008735.ref009" ref-type="bibr">9</xref>, <xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>, <xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="ppat.1008735.ref023" ref-type="bibr">23</xref>].</p><fig id="ppat.1008735.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1008735.g001</object-id><label>Fig 1</label><caption><title>Notable historic uses of antibody therapy against infectious diseases.</title><p>COVID-19, coronavirus disease 2019; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.</p></caption><graphic xlink:href="ppat.1008735.g001"/></fig></sec><sec id="sec003"><title>Buying time with the help of the convalescent</title><p>The convalescent plasma therapeutic approach is based on the principle of passive antibody therapy, a short-term strategy whereby antibodies from the blood of someone who recovered from an infection can be administered to protect or treat another person [<xref rid="ppat.1008735.ref006" ref-type="bibr">6</xref>, <xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>]. Effectively, the end goal is the same as vaccines, making antibodies against a specific infectious agent readily available. For instance, a vaccine relies on the host immune cells (B lymphocytes specifically) to produce antibodies after antigen recognition and signal amplification by the immune system, a process that may take weeks [<xref rid="ppat.1008735.ref024" ref-type="bibr">24</xref>]; on the other hand, in the case of passive antibody therapy, the process is expedited by providing a patient with immediate immunity when the premade antibodies are given. Therefore, for COVID-19 patients, the expedited approach could prove lifesaving. Nevertheless, this advantage does not come without caveats, as immunization with passive antibody therapy is typically of shorter-term protection, in part because of the half-life of antibodies in circulation [<xref rid="ppat.1008735.ref025" ref-type="bibr">25</xref>] and lack of new production by B lymphocytes. Today, passive antibody therapy relies primarily on pooled immunoglobulin preparations that contain high concentrations of antibodies. In contrast, plasma has been used emergently in epidemics in which there is insufficient time or resources to generate immunoglobulin preparations [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>].</p><p>Despite the high rate of SARS-CoV-2 infection, the relatively low mortality rate provides a rich pool of donors [<xref rid="ppat.1008735.ref026" ref-type="bibr">26</xref>]. However, potential COVID-19 donors must meet several eligibility criteria that ensure the donor has antibodies against SARS-CoV-2 and lacks the presence of other types of infections [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>, <xref rid="ppat.1008735.ref027" ref-type="bibr">27</xref>]. Additionally, only plasma with high anti-SARS-CoV-2 titers of immunoglobulins G and M (IgG and IgM) are used. Once collected, plasma can be tested and administered within hours, following conventional donor&#x02013;patient blood compatibility typing [<xref rid="ppat.1008735.ref027" ref-type="bibr">27</xref>]. In addition to rapid mobilization, this therapeutic approach is also versatile in applicability as it can be used for prophylaxis or treatment, as illustrated in <xref ref-type="fig" rid="ppat.1008735.g002">Fig 2</xref>. In the case of prophylaxis, a subject considered at high risk for infection (because of age or underlying medical conditions or who is likely to be in contact with people with COVID-19) could be administered convalescent plasma or neutralizing antibodies for protection against infection. Alternatively, plasma can be administered to treat subjects who have contracted the infection but have not made sufficient antibodies against the virus yet in order to augment their immune response, improve disease course, and enhance recovery [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>]. However, it is important to note that passive antibody therapy is most effective when administered prophylactically or implemented early after the onset of symptoms [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>].</p><fig id="ppat.1008735.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1008735.g002</object-id><label>Fig 2</label><caption><title>Overview of the use and applications of CP therapy.</title><p>Virus-neutralizing antibodies in the plasma of a patient who recovered from COVID-19 can be administered prophylactically to prevent infection in vulnerable individuals and those with known exposure to the virus (Prophylaxis). Convalescent plasma can also be administered to infected individuals to improve the clinical outcome (Treatment). CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></caption><graphic xlink:href="ppat.1008735.g002"/></fig><p>Convalescent plasma with neutralizing antibodies is currently being used for investigational purposes in the COVID-19 pandemic, and preliminary results from 2 small studies performed in China are encouraging. A pilot study exploring the feasibility of convalescent plasma transfusion to rescue a group of 10 patients with severe disease showed that 1 dose (200 mL) of convalescent plasma with high neutralizing antibody titers was well tolerated, resulted in disappearance of viremia, and improved clinical symptoms in all patients within days of administration [<xref rid="ppat.1008735.ref008" ref-type="bibr">8</xref>]. Similar results were reported from another study with 5 critically ill patients on mechanical ventilation [<xref rid="ppat.1008735.ref007" ref-type="bibr">7</xref>]. Although these small, nonrandomized studies had limitations, these findings indicate that convalescent plasma could be a promising rescue option for severe COVID-19 [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>].</p></sec><sec id="sec004"><title>Limitations and potential risks</title><p>Although convalescent plasma therapy is considered a relatively safe therapeutic modality, there are some potential risks [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>]. One theoretical complication that may arise is an antibody-mediated proinflammatory disease enhancement known as antibody-dependent enhancement (ADE), whereby antibodies that developed during a prior infection exacerbate severity of the disease [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>, <xref rid="ppat.1008735.ref028" ref-type="bibr">28</xref>]. The transfer of these antibodies may aberrantly activate fragment crystallizable (Fc) or complement receptors, increasing recruitment of proinflammatory cytokines and chemokines to the site of infection and causing severe tissue damage [<xref rid="ppat.1008735.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="ppat.1008735.ref031" ref-type="bibr">31</xref>]. Additionally, the presence of non-neutralizing antibodies may exacerbate viral endocytosis or phagocytosis into host cells via Fc receptors, potentializing viral replication [<xref rid="ppat.1008735.ref029" ref-type="bibr">29</xref>, <xref rid="ppat.1008735.ref032" ref-type="bibr">32</xref>]. However, although this phenomenon is well known with Dengue and other viral diseases, there have not been any reported ADE cases with the use of convalescent plasma for SARS, MERS, or COVID-19 [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>, <xref rid="ppat.1008735.ref029" ref-type="bibr">29</xref>, <xref rid="ppat.1008735.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="ppat.1008735.ref035" ref-type="bibr">35</xref>]. Nevertheless, it is crucial to have a clear understanding of the role of the recipients' immune response [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>]. Transmission of the virus through transfusion is another concern; however, the risk is relatively low because of strict transfusion protocols, and when used for treatment purposes, the recipient is already infected [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>, <xref rid="ppat.1008735.ref036" ref-type="bibr">36</xref>].</p><p>The success of convalescent plasma therapy hinges on the availability of plasma with high concentrations of antibodies, which may not be a major limitation for COVID-19 because SARS-CoV-2 has been shown to elicit high neutralizing antibody titers in recently convalesced individuals [<xref rid="ppat.1008735.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="ppat.1008735.ref009" ref-type="bibr">9</xref>]. Apheresis is an automated technology that allows for selective collection of a blood fraction while other components can be transfused back to the donor. Therefore, for donation of convalescent plasma, plasmapheresis is recommended because it is highly efficient and approximately 400&#x02013;800 mL of plasma can be collected in a single donation, providing 2&#x02013;4 units of convalescent plasma for transfusion [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>]. There are some practical and logistical limitations for the implementation of a large-scale convalescent plasma transfusion program such as training of study personnel, recruitment of donors, and transport of plasma to hospitals, as well considerations for plasma shelf-life and half-life of antibodies in the plasma [<xref rid="ppat.1008735.ref021" ref-type="bibr">21</xref>, <xref rid="ppat.1008735.ref036" ref-type="bibr">36</xref>].</p><p>Although large-scale randomized clinical trials will ultimately confirm the safety and efficacy of convalescent plasma therapy for COVID-19, a recent safety study by Joyner and colleagues [<xref rid="ppat.1008735.ref012" ref-type="bibr">12</xref>] provided encouraging data. By analyzing key safety metrics following transfusion of convalescent plasma in 5,000 hospitalized adults with severe or life-threatening COVID-19, the incidence of serious adverse events was found to be &#x0003c;1%, and the 7-day mortality incidence was 14.9%. These early indicators are encouraging and highly supportive of the use of convalescent plasma as a rescue therapy in hospitalized patients, given that the reported fatality rate of COVID-19 among patients admitted to the intensive care units (ICUs) is 57% [<xref rid="ppat.1008735.ref037" ref-type="bibr">37</xref>]. In fact, the low risk indicated by the study support expanding the use of convalescent plasma therapy in less ill individuals [<xref rid="ppat.1008735.ref006" ref-type="bibr">6</xref>].</p></sec><sec id="sec005"><title>Future perspectives</title><p>The global reach of the COVID-19 pandemic and the desperate need for effective treatments have provided an impetus to develop convalescent plasma therapy into a viable (albeit short-term) treatment option particularly for the critically ill. Although its efficacy and safety have not yet been fully proven, convalescent plasma therapy for COVID-19 patients is projected to be a safe and potentially effective therapy for prophylaxis and treatment. However, it is critically important to perform rigorous randomized controlled trials to confirm efficacy and safety and to provide evidence for improved meaningful clinical outcomes. Nevertheless, despite the nuanced challenges, the substantial evidence of benefit with use for prior viral infections offers strong precedent for convalescent plasma as a therapeutic approach. Importantly, efforts should be focused not only on evaluation of the feasibility of plasma treatment for infectious diseases but also ensure that use of convalescent plasma therapy takes place according to ethical and controlled conditions.</p></sec></body><back><ack><p>We would like to thank Dr. Arturo Casadevall for critical review of the manuscript.</p></ack><ref-list><title>References</title><ref id="ppat.1008735.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>R</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Niu</surname><given-names>P</given-names></name>, <name><surname>Yang</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10224</issue>):<fpage>565</fpage>&#x02013;<lpage>74</lpage>. Epub 2020/02/03. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id>
<?supplied-pmid 32007145?><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Peeri</surname><given-names>NC</given-names></name>, <name><surname>Shrestha</surname><given-names>N</given-names></name>, <name><surname>Rahman</surname><given-names>MS</given-names></name>, <name><surname>Zaki</surname><given-names>R</given-names></name>, <name><surname>Tan</surname><given-names>Z</given-names></name>, <name><surname>Bibi</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?</article-title>
<source>Int J Epidemiol</source>. <year>2020</year> Epub 2020/02/23. <pub-id pub-id-type="doi">10.1093/ije/dyaa033</pub-id> .<?supplied-pmid 32086938?><pub-id pub-id-type="pmid">32086938</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Shi</surname><given-names>ZL</given-names></name>. <article-title>Origin and evolution of pathogenic coronaviruses</article-title>. <source>Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02013;<lpage>92</lpage>. Epub 2018/12/12. <pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id>
<?supplied-pmid 30531947?><pub-id pub-id-type="pmid">30531947</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>K</given-names></name>, <name><surname>Shi</surname><given-names>ZL</given-names></name>, <name><surname>Zhou</surname><given-names>P</given-names></name>. <article-title>Bat Coronaviruses in China</article-title>. <source>Viruses</source>. <year>2019</year>;<volume>11</volume>(<issue>3</issue>). Epub 2019/03/06. <pub-id pub-id-type="doi">10.3390/v11030210</pub-id>
<?supplied-pmid 30832341?><pub-id pub-id-type="pmid">30832341</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Beigel</surname><given-names>JH</given-names></name>, <name><surname>Tomashek</surname><given-names>KM</given-names></name>, <name><surname>Dodd</surname><given-names>LE</given-names></name>, <name><surname>Mehta</surname><given-names>AK</given-names></name>, <name><surname>Zingman</surname><given-names>BS</given-names></name>, <name><surname>Kalil</surname><given-names>AC</given-names></name>, <etal>et al</etal>
<article-title>Remdesivir for the Treatment of Covid-19&#x02014;Preliminary Report</article-title>. <source>N Engl J Med</source>. <year>2020</year> Epub 2020/05/24. <pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id>
<?supplied-pmid 32445440?><pub-id pub-id-type="pmid">32445440</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Casadevall</surname><given-names>A</given-names></name>, <name><surname>Pirofski</surname><given-names>LA</given-names></name>. <article-title>The convalescent sera option for containing COVID-19</article-title>. <source>J Clin Invest</source>. <year>2020</year>;<volume>130</volume>(<issue>4</issue>):<fpage>1545</fpage>&#x02013;<lpage>1548</lpage>. Epub 2020/03/14. <pub-id pub-id-type="doi">10.1172/JCI138003</pub-id> .<?supplied-pmid 32167489?><pub-id pub-id-type="pmid">32167489</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Zhao</surname><given-names>F</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Yuan</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>16</issue>):<fpage>1582</fpage>&#x02013;<lpage>1589</lpage>. Epub 2020/03/29. <pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id>
<?supplied-pmid 32219428?><pub-id pub-id-type="pmid">32219428</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Duan</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Yu</surname><given-names>T</given-names></name>, <name><surname>Qu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>(<issue>17</issue>):<fpage>9490</fpage>&#x02013;<lpage>9496</lpage>. Epub 2020/04/08. <pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id> .<?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Pang</surname><given-names>R</given-names></name>, <name><surname>Xue</surname><given-names>X</given-names></name>, <name><surname>Bao</surname><given-names>J</given-names></name>, <name><surname>Ye</surname><given-names>S</given-names></name>, <name><surname>Dai</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19</article-title>. <source>Aging</source>. <year>2020</year>;<volume>12</volume>(<issue>8</issue>):<fpage>6536</fpage>&#x02013;<lpage>6542</lpage>. Epub 2020/04/23. <pub-id pub-id-type="doi">10.18632/aging.103102</pub-id> .<?supplied-pmid 32320384?><pub-id pub-id-type="pmid">32320384</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>M</given-names></name>, <name><surname>Fu</surname><given-names>D</given-names></name>, <name><surname>Ren</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>F</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Treatment with convalescent plasma for COVID-19 patients in Wuhan, China</article-title>. <source>J Med Virol</source>. <year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>12</lpage>. Epub 2020/04/16. <pub-id pub-id-type="doi">10.1002/jmv.25577</pub-id> .<?supplied-pmid 31502247?><pub-id pub-id-type="pmid">31502247</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Sheridan</surname><given-names>C.</given-names></name>
<article-title>Convalescent serum lines up as first-choice treatment for coronavirus</article-title>. <source>Nat Biotechnol</source>. <year>2020</year>;(<issue>38</issue>):<fpage>655</fpage>&#x02013;<lpage>658</lpage>. Epub 2020/05/03. <pub-id pub-id-type="doi">10.1038/d41587-020-00011-1</pub-id> .<?supplied-pmid 32358594?><pub-id pub-id-type="pmid">32358594</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Joyner</surname><given-names>M</given-names></name>, <name><surname>Wright</surname><given-names>RS</given-names></name>, <name><surname>Fairweather</surname><given-names>D</given-names></name>, <name><surname>Senefeld</surname><given-names>J</given-names></name>, <name><surname>Bruno</surname><given-names>K</given-names></name>, <name><surname>Klassen</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients</article-title>. <source>medRxiv</source>
<year>2020</year><month>5</month><day>12</day>20099879 [Preprint]. 2020 [cited 2020 May 16]. <pub-id pub-id-type="doi">10.1101/2020.05.12.20099879</pub-id>
<?supplied-pmid 32511566?><pub-id pub-id-type="pmid">32511566</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Behring</surname><given-names>Ev</given-names></name>. <source>Ueber das Zustandekommen der Diphtherie-Immunit&#x000e4;t und der Tetanus-Immunit&#x000e4;t bei Thieren</source>. <year>2013</year>
<pub-id pub-id-type="doi">10.17192/eb2013.0164</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref014"><label>14</label><mixed-citation publication-type="book"><name><surname>Behring</surname><given-names>Ev</given-names></name>. <source>Untersuchungen &#x000fc;ber das Zustandekommen der Diphtherie-Immunit&#x000e4;t bei Thiere</source>. <publisher-name>Philipps-Universit&#x000e4;t Marburg</publisher-name>
<year>2013</year>
<pub-id pub-id-type="doi">10.17192/eb2013.0165</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>SH</given-names></name>. <article-title>Remembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes</article-title>. <source>mBio</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>). Epub 2017/03/02. <pub-id pub-id-type="doi">10.1128/mBio.00117-17</pub-id>
<?supplied-pmid 28246359?><pub-id pub-id-type="pmid">28246359</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>JJ</given-names></name>. <article-title>The Action of Vaccines and of Concentrated Antistreptococcus Serum in Experimental Streptococcal Arthritis</article-title>. <source>J Infect Dis</source>. <year>1914</year>;<volume>15</volume>(<issue>1</issue>):<fpage>215</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="ppat.1008735.ref017"><label>17</label><mixed-citation publication-type="other">Smith DD. Serum treatment of scarlet fever [doctoral thesis]. Omaha (Nebraska): University of Nebraska; 1934.</mixed-citation></ref><ref id="ppat.1008735.ref018"><label>18</label><mixed-citation publication-type="journal"><article-title>The use of convalescent serum in the treatment of measles, chickenpox, mumps and whooping cough, including the prophylactic value of parental blood</article-title>: J. M. and <name><surname>Barenberg</surname><given-names>L. H.</given-names></name> N. Y. State J. Med. 33: 2, 1933. <source>Int J Orthod Dent Child</source>. <year>1933</year>;<volume>19</volume>(<issue>3</issue>):<fpage>328</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0097-0522(33)90316-0</pub-id> PubMed PMID: S0097052233903160.</mixed-citation></ref><ref id="ppat.1008735.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Kohn</surname><given-names>JL</given-names></name>, <name><surname>Klein</surname><given-names>IF</given-names></name>, <name><surname>Schwarz</surname><given-names>H</given-names></name>. <article-title>Treatment of preeruptive measles with convalescent serum</article-title>. <source>JAMA</source>. <year>1938</year>;<volume>111</volume>(<issue>26</issue>):<fpage>2361</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1938.02790520017004</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Casadevall</surname><given-names>A</given-names></name>, <name><surname>Scharff</surname><given-names>MD</given-names></name>. <article-title>Serum therapy revisited: animal models of infection and development of passive antibody therapy</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1994</year>;<volume>38</volume>(<issue>8</issue>):<fpage>1695</fpage>&#x02013;<lpage>702</lpage>. Epub 1994/08/01. <pub-id pub-id-type="doi">10.1128/aac.38.8.1695</pub-id>
<?supplied-pmid 7985997?><pub-id pub-id-type="pmid">7985997</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bloch</surname><given-names>EM</given-names></name>, <name><surname>Shoham</surname><given-names>S</given-names></name>, <name><surname>Casadevall</surname><given-names>A</given-names></name>, <name><surname>Sachais</surname><given-names>BS</given-names></name>, <name><surname>Shaz</surname><given-names>B</given-names></name>, <name><surname>Winters</surname><given-names>JL</given-names></name>, <etal>et al</etal>
<article-title>Deployment of convalescent plasma for the prevention and treatment of COVID-19</article-title>. <source>J Clin Invest</source>. <year>2020</year> Epub 2020/04/08. <pub-id pub-id-type="doi">10.1172/JCI138745</pub-id> .<?supplied-pmid 32254064?><pub-id pub-id-type="pmid">32254064</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Hung</surname><given-names>IF</given-names></name>, <name><surname>To</surname><given-names>KK</given-names></name>, <name><surname>Lee</surname><given-names>CK</given-names></name>, <name><surname>Lee</surname><given-names>KL</given-names></name>, <name><surname>Chan</surname><given-names>K</given-names></name>, <name><surname>Yan</surname><given-names>WW</given-names></name>, <etal>et al</etal>
<article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>(<issue>4</issue>):<fpage>447</fpage>&#x02013;<lpage>56</lpage>. Epub 2011/01/21. <pub-id pub-id-type="doi">10.1093/cid/ciq106</pub-id> .<?supplied-pmid 21248066?><pub-id pub-id-type="pmid">21248066</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Hung</surname><given-names>IFN</given-names></name>, <name><surname>To</surname><given-names>KKW</given-names></name>, <name><surname>Lee</surname><given-names>CK</given-names></name>, <name><surname>Lee</surname><given-names>KL</given-names></name>, <name><surname>Yan</surname><given-names>WW</given-names></name>, <name><surname>Chan</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection</article-title>. <source>Chest</source>. <year>2013</year>;<volume>144</volume>(<issue>2</issue>):<fpage>464</fpage>&#x02013;<lpage>73</lpage>. Epub 2013/03/02. <pub-id pub-id-type="doi">10.1378/chest.12-2907</pub-id> .<?supplied-pmid 23450336?><pub-id pub-id-type="pmid">23450336</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref024"><label>24</label><mixed-citation publication-type="other">Prevention CfDCa. Principles of Vaccination. In: Epidemiology and Prevention of Vaccine-Preventable Diseases [Internet]. Washington, D.C.: Public Health Foundation. 13th. [cited 2020 June 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccines/pubs/pinkbook/prinvac.html">https://www.cdc.gov/vaccines/pubs/pinkbook/prinvac.html</ext-link></mixed-citation></ref><ref id="ppat.1008735.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Chames</surname><given-names>P</given-names></name>, <name><surname>Van Regenmortel</surname><given-names>M</given-names></name>, <name><surname>Weiss</surname><given-names>E</given-names></name>, <name><surname>Baty</surname><given-names>D</given-names></name>. <article-title>Therapeutic antibodies: successes, limitations and hopes for the future</article-title>. <source>Br J Pharmacol</source>. <year>2009</year>;<volume>157</volume>(<issue>2</issue>):<fpage>220</fpage>&#x02013;<lpage>33</lpage>. Epub 2009/05/23. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00190.x</pub-id>
<?supplied-pmid 19459844?><pub-id pub-id-type="pmid">19459844</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lai</surname><given-names>CC</given-names></name>, <name><surname>Shih</surname><given-names>TP</given-names></name>, <name><surname>Ko</surname><given-names>WC</given-names></name>, <name><surname>Tang</surname><given-names>HJ</given-names></name>, <name><surname>Hsueh</surname><given-names>PR</given-names></name>. <article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</article-title>. <source>Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>(<issue>3</issue>):<fpage>105924</fpage> Epub 2020/02/23. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105924</pub-id>
<?supplied-pmid 32081636?><pub-id pub-id-type="pmid">32081636</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Epstein</surname><given-names>J</given-names></name>, <name><surname>Burnouf</surname><given-names>T</given-names></name>. <article-title>Points to consider in the preparation and transfusion of COVID-19 convalescent plasma</article-title>. <source>Vox Sang</source>. <year>2020</year> Epub 2020/04/23. <pub-id pub-id-type="doi">10.1111/vox.12939</pub-id> .<?supplied-pmid 32319102?><pub-id pub-id-type="pmid">32319102</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>X.</given-names></name>
<article-title>COVID-19: immunopathology and its implications for therapy</article-title>. <source>Nat Rev Immunol</source>. <year>2020</year>;<volume>20</volume>(<issue>5</issue>):<fpage>269</fpage>&#x02013;<lpage>70</lpage>. Epub 2020/04/11. <pub-id pub-id-type="doi">10.1038/s41577-020-0308-3</pub-id>
<?supplied-pmid 32273594?><pub-id pub-id-type="pmid">32273594</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>de Alwis</surname><given-names>R</given-names></name>, <name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Gan</surname><given-names>ES</given-names></name>, <name><surname>Ooi</surname><given-names>EE</given-names></name>. <article-title>Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development</article-title>. <source>EBioMedicine</source>. <year>2020</year>;<volume>55</volume>:<fpage>102768</fpage> Epub 2020/04/29. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102768</pub-id>
<?supplied-pmid 32344202?><pub-id pub-id-type="pmid">32344202</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Lutz</surname><given-names>HU</given-names></name>. <article-title>How immune complexes from certain IgG NAbs and any F(ab')(2) can mediate excessive complement activation</article-title>. <source>Adv Exp Med Biol</source>. <year>2012</year>;<volume>750</volume>:<fpage>186</fpage>&#x02013;<lpage>96</lpage>. Epub 2012/08/21. <pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_14</pub-id>
<?supplied-pmid 22903675?><pub-id pub-id-type="pmid">22903675</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Jancar</surname><given-names>S</given-names></name>, <name><surname>Sanchez Crespo</surname><given-names>M</given-names></name>. <article-title>Immune complex-mediated tissue injury: a multistep paradigm</article-title>. <source>Trends Immunol</source>. <year>2005</year>;<volume>26</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>55</lpage>. Epub 2005/01/05. <pub-id pub-id-type="doi">10.1016/j.it.2004.11.007</pub-id> .<?supplied-pmid 15629409?><pub-id pub-id-type="pmid">15629409</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Yip</surname><given-names>MS</given-names></name>, <name><surname>Leung</surname><given-names>HL</given-names></name>, <name><surname>Li</surname><given-names>PH</given-names></name>, <name><surname>Cheung</surname><given-names>CY</given-names></name>, <name><surname>Dutry</surname><given-names>I</given-names></name>, <name><surname>Li</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS</article-title>. <source>Hong Kong Med J</source>. <year>2016</year>;<volume>22</volume>(<issue>3</issue> Suppl 4):<fpage>25</fpage>&#x02013;<lpage>31</lpage>. Epub 2016/07/09. .<?supplied-pmid 27390007?><pub-id pub-id-type="pmid">27390007</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Katzelnick</surname><given-names>LC</given-names></name>, <name><surname>Harris</surname><given-names>E</given-names></name>, <article-title>Participants in the Summit on Dengue Immune Correlates of P. Immune correlates of protection for dengue: State of the art and research agenda</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>36</issue>):<fpage>4659</fpage>&#x02013;<lpage>69</lpage>. Epub 2017/08/02. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.07.045</pub-id>
<?supplied-pmid 28757058?><pub-id pub-id-type="pmid">28757058</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Tetro</surname><given-names>JA</given-names></name>. <article-title>Is COVID-19 receiving ADE from other coronaviruses?</article-title>
<source>Microbes Infect</source>. 2020;<volume>22</volume>(<issue>2</issue>):<fpage>72</fpage>&#x02013;<lpage>3</lpage>. Epub 2020/02/25. <pub-id pub-id-type="doi">10.1016/j.micinf.2020.02.006</pub-id>
<?supplied-pmid 32092539?><pub-id pub-id-type="pmid">32092539</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Halstead</surname><given-names>SB</given-names></name>, <name><surname>O'Rourke</surname><given-names>EJ</given-names></name>. <article-title>Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody</article-title>. <source>J Exp Med</source>. <year>1977</year>;<volume>146</volume>(<issue>1</issue>):<fpage>201</fpage>&#x02013;<lpage>17</lpage>. Epub 1977/07/01. <pub-id pub-id-type="doi">10.1084/jem.146.1.201</pub-id>
<?supplied-pmid 406347?><pub-id pub-id-type="pmid">406347</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Marano</surname><given-names>G</given-names></name>, <name><surname>Vaglio</surname><given-names>S</given-names></name>, <name><surname>Pupella</surname><given-names>S</given-names></name>, <name><surname>Facco</surname><given-names>G</given-names></name>, <name><surname>Catalano</surname><given-names>L</given-names></name>, <name><surname>Liumbruno</surname><given-names>GM</given-names></name>, <etal>et al</etal>
<article-title>Convalescent plasma: new evidence for an old therapeutic tool?</article-title>
<source>Blood Transfus</source>. <year>2016</year>;<volume>14</volume>(<issue>2</issue>):<fpage>152</fpage>&#x02013;<lpage>7</lpage>. Epub 2015/12/18. <pub-id pub-id-type="doi">10.2450/2015.0131-15</pub-id>
<?supplied-pmid 26674811?><pub-id pub-id-type="pmid">26674811</pub-id></mixed-citation></ref><ref id="ppat.1008735.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Yu</surname><given-names>Y</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Shu</surname><given-names>H</given-names></name>, <name><surname>Xia</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med</source>. <year>2020</year>;<volume>8</volume>(<issue>5</issue>):<fpage>475</fpage>&#x02013;<lpage>81</lpage>. Epub 2020/02/28. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id>
<?supplied-pmid 32105632?><pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref></ref-list></back></article>